Cargando…

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

SUMMARY: A novel cost-effectiveness model framework was developed to incorporate the elevated fracture risk associated with a recent fracture and to allow sequential osteoporosis therapies to be evaluated. Treating patients with severe osteoporosis after a recent fracture with a bone-forming agent f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Söreskog, E., Borgström, F., Lindberg, I., Ström, O., Willems, D., Libanati, C., Kanis, J. A., Stollenwerk, B., Charokopou, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192365/ https://www.ncbi.nlm.nih.gov/pubmed/33411005 http://dx.doi.org/10.1007/s00198-020-05765-7

Ejemplares similares

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting
por: Banefelt, Jonas, et al.
Publicado: (2021)

Hospitalizations for osteoporosis-related fractures: Economic costs and clinical outcomes
por: Weycker, Derek, et al.
Publicado: (2016)

A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)
por: Talevski, J., et al.
Publicado: (2022)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
por: Rizzoli, R., et al.
Publicado: (2010)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures
por: Nshimyumukiza, Léon, et al.
Publicado: (2013)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

SCOPE: a scorecard for osteoporosis in Europe
por: Kanis, J. A., et al.
Publicado: (2013)

Osteoporosis in Europe: a compendium of country-specific reports
por: Willers, Carl, et al.
Publicado: (2022)

SCOPE 2021: a new scorecard for osteoporosis in Europe
por: Kanis, John A., et al.
Publicado: (2021)

Economic burden of osteoporotic fractures in Austria
por: Dimai, Hans Peter, et al.
Publicado: (2012)

Osteoporosis associated vertebral fractures—Health economic implications
por: Joestl, Julian, et al.
Publicado: (2017)

Fracture Risk in Men and Women With Vertebral Fractures Identified Opportunistically on Routine Computed Tomography Scans and Not Treated for Osteoporosis: An Observational Cohort Study
por: Skjødt, Michael Kriegbaum, et al.
Publicado: (2023)

Real-world outcomes in spinal cord stimulation: predictors of reported effect and explantation using a comprehensive registry-based approach
por: Kirketeig, Terje, et al.
Publicado: (2023)

Textbook of osteoporosis
por: Kanis, John A. (John Anthony), 1944-
Publicado: (1996)

Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health
por: Kostenuik, Paul J., et al.
Publicado: (2023)

Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
por: Williams, Setareh A., et al.
Publicado: (2020)

The Costs of Confronting Osteoporosis: Cost Study of an Australian Fracture Liaison Service
por: Major, Gabor, et al.
Publicado: (2018)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Impact of spinal cord stimulation on sick leave and disability pension in patients with chronic neuropathic pain: a real-world evidence study in Sweden
por: Söreskog, Emma, et al.
Publicado: (2023)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Commentary on guidelines on postmenopausal osteoporosis - Indian Menopause Society
por: Kanis, John
Publicado: (2013)

Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
por: Nakao, Motoyuki, et al.
Publicado: (2018)

Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
por: Nguyen, Vu H.
Publicado: (2018)

Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
por: Hiligsmann, M., et al.
Publicado: (2018)

Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective
por: Connolly, Mark P., et al.
Publicado: (2019)

Risk of imminent fracture following a previous fracture in a Swedish database study
por: Banefelt, J., et al.
Publicado: (2019)

Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
por: Hernlund, E., et al.
Publicado: (2013)

Quality of life after fragility fracture in the Russian Federation: results from the Russian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (ICUROS)
por: Lesnyak, Olga, et al.
Publicado: (2020)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Estimations of bone mineral density defined osteoporosis prevalence and cutpoint T-score for defining osteoporosis among older Chinese population: a framework based on relative fragility fracture risks
por: Wáng, Yì Xiáng J., et al.
Publicado: (2022)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada
por: Coyle, Doug
Publicado: (2019)

Economic inequalities amongst women with osteoporosis-related fractures: an application of concentration index decomposition
por: Moradzadeh, Rahmatollah, et al.
Publicado: (2016)

Osteoanabolic Agents for Osteoporosis
por: Haas, Andrea V, et al.
Publicado: (2018)

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pjkkch91ujo5uvsh1c59l5k343